Cwm LLC Sells 198 Shares of Celgene Co. (NASDAQ:CELG)

Cwm LLC reduced its position in shares of Celgene Co. (NASDAQ:CELG) by 8.0% in the third quarter, HoldingsChannel reports. The firm owned 2,277 shares of the biopharmaceutical company’s stock after selling 198 shares during the quarter. Cwm LLC’s holdings in Celgene were worth $226,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also recently added to or reduced their stakes in CELG. Renaissance Technologies LLC grew its stake in shares of Celgene by 85.7% during the 2nd quarter. Renaissance Technologies LLC now owns 8,935,785 shares of the biopharmaceutical company’s stock valued at $826,024,000 after purchasing an additional 4,122,685 shares during the period. Nuveen Asset Management LLC grew its stake in shares of Celgene by 707.3% during the 2nd quarter. Nuveen Asset Management LLC now owns 4,476,814 shares of the biopharmaceutical company’s stock valued at $413,836,000 after purchasing an additional 3,922,247 shares during the period. York Capital Management Global Advisors LLC grew its stake in shares of Celgene by 854.8% during the 2nd quarter. York Capital Management Global Advisors LLC now owns 2,588,825 shares of the biopharmaceutical company’s stock valued at $239,311,000 after purchasing an additional 2,317,676 shares during the period. TIG Advisors LLC grew its stake in shares of Celgene by 77.3% during the 2nd quarter. TIG Advisors LLC now owns 3,583,622 shares of the biopharmaceutical company’s stock valued at $331,270,000 after purchasing an additional 1,562,004 shares during the period. Finally, Omni Partners LLP grew its stake in shares of Celgene by 207.0% during the 2nd quarter. Omni Partners LLP now owns 1,842,219 shares of the biopharmaceutical company’s stock valued at $170,295,000 after purchasing an additional 1,242,219 shares during the period. Institutional investors and hedge funds own 72.49% of the company’s stock.

In other news, insider Terrie Curran sold 11,338 shares of Celgene stock in a transaction dated Wednesday, September 18th. The stock was sold at an average price of $98.27, for a total transaction of $1,114,185.26. Following the transaction, the insider now directly owns 13,493 shares of the company’s stock, valued at approximately $1,325,957.11. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.39% of the stock is owned by insiders.

CELG stock opened at $105.70 on Tuesday. Celgene Co. has a twelve month low of $58.59 and a twelve month high of $107.41. The company has a quick ratio of 3.32, a current ratio of 3.44 and a debt-to-equity ratio of 1.97. The stock has a market cap of $74.08 billion, a P/E ratio of 13.89, a PEG ratio of 0.53 and a beta of 1.42. The business’s 50-day moving average price is $100.36 and its 200-day moving average price is $95.99.

Celgene (NASDAQ:CELG) last posted its quarterly earnings data on Tuesday, July 30th. The biopharmaceutical company reported $2.61 earnings per share for the quarter, beating the Zacks’ consensus estimate of $2.44 by $0.17. Celgene had a return on equity of 89.93% and a net margin of 32.24%. The firm had revenue of $4.40 billion for the quarter, compared to analysts’ expectations of $4.22 billion. During the same period in the previous year, the firm earned $2.16 EPS. The business’s quarterly revenue was up 15.4% on a year-over-year basis. On average, equities research analysts expect that Celgene Co. will post 9.96 earnings per share for the current fiscal year.

CELG has been the subject of a number of recent research reports. Mizuho restated a “hold” rating and set a $100.00 price target on shares of Celgene in a research note on Sunday, October 20th. Cowen restated a “hold” rating and set a $102.00 price target on shares of Celgene in a research note on Tuesday, July 30th. Zacks Investment Research upgraded Celgene from a “sell” rating to a “hold” rating and set a $94.00 price target for the company in a research note on Tuesday, July 23rd. ValuEngine downgraded Celgene from a “sell” rating to a “strong sell” rating in a research note on Thursday, August 1st. Finally, BidaskClub upgraded Celgene from a “hold” rating to a “buy” rating in a research note on Tuesday, October 1st. One investment analyst has rated the stock with a sell rating, seventeen have issued a hold rating and three have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $93.26.

Celgene Company Profile

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers.

Featured Story: Mutual Funds

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.